Skip to main content

Table 3 Pharmacodynamic parameters in COPD patients treated with V0162 versus placebo

From: V0162 a new long-acting bronchodilator for treatment of chronic obstructive lung diseases: preclinical and clinical results

COPD patients

 

V0162 (n = 20)

Placebo (n = 20)

p-value

FEV1

   

 AUC30min/6h, L

1.36 ± 0.13

1.26 ± 0.11

0.004

 AUC30min/9h, L

1.36 ± 0.12

1.26 ± 0.12

0.003

 AUC30min/22h, L

1.33 ± 0.12

1.24 ± 0.12

0.006

 AUC30min/28h, L

1.34 ± 0.12

1.25 ± 0.12

0.007

 AUC30min/32h, L

1.35 ± 0.12

1.27 ± 0.12

0.006

Trough FEV1, L

1.19 ± 0.11

1.11 ± 0.11

0.016

FVC

   

 AUC30min/6h, L

3.01 ± 0.20

2.86 ± 0.18

0.019

 AUC30min/9h, L

3.01 ± 0.19

2.87 ± 0.19

0.011

 AUC30min/22h, L

2.96 ± 0.18

2.83 ± 0.18

0.017

 AUC30min/28h, L

2.96 ± 0.19

2.84 ± 0.18

0.013

 AUC30min/32h, L

2.98 ± 0.19

2.85 ± 0.19

0.014

FRC

   

 AUC30min/6h, L

5.24 ± 0.23

5.45 ± 0.29

<0.001

 AUC30min/9h, L

5.25 ± 0.25

5.51 ± 0.25

<0.001

 AUC30min/22h, L

5.34 ± 0.24

5.52 ± 0.24

0.006

 AUC30min/28h, L

5.21 ± 0.24

5.43 ± 0.29

0.003

 AUC30min/32h, L

5.22 ± 0.24

5.41 ± 0.29

0.003

Dyspnea

   

 nIAUC30min/6h, mm

- 17.79 ± 5.26

- 11.44 ± 5.27

0.161

 nIAUC30min/9h, mm

- 18.08 ± 5.31

- 10.93 ± 5.31

0.084

 nIAUC30min/22h, mm

- 17.45 ± 5.97

- 9.72 ± 5.97

0.054

 nIAUC30min/28h, mm

- 17.33 ± 6.04

- 9.43 ± 6.04

0.057

 nIAUC30min/32h, mm

- 17.45 ± 6.03

- 10.193 ± 6.03

0.078

  1. Results are presented by mean ± SE